Physician profile
Ashley E Doyle
NPI 1790226652
$6,891.81
in general payments reported to CMS, 2019-2025
35 companies · $2,734 in 2025
The $2,734 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $359 · 2022: $569 · 2023: $1,163 · 2024: $2,067 · 2025: $2,734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,964.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $775.76 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $625.50 | 2021-2022 | |
| Bausch Health US, LLC | $563.62 | 2023-2025 | Aplenzin, Wellbutrin |
| Novo Nordisk INC | $560.52 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Alkermes, INC. | $505.48 | 2023-2025 | Lybalvi, Aristada, Vivitrol |
| Axsome Therapeutics, INC. | $491.18 | 2022-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $428.93 | 2023-2025 | Trintellix |
| Tris Pharma INC | $410.87 | 2023-2025 | Dyanavel Xr |
| Otsuka America Pharmaceutical, INC. | $261.10 | 2023-2025 | Rexulti, Nuedexta |
| Ironshore Pharmaceuticals INC. | $209.09 | 2022-2024 | |
| Lundbeck LLC | $190.52 | 2023-2025 | Rexulti |
| Collegium Pharmaceutical, INC. | $186.84 | 2025 | Jornay Pm |
| Astrazeneca Pharmaceuticals Lp | $180.88 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $173.92 | 2022-2025 | Caplyta |
| Lilly USA, LLC | $172.79 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $159.93 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Myovant Sciences INC. | $115.82 | 2022 | |
| Supernus Pharmaceuticals, INC. | $101.31 | 2022-2025 | Qelbree, Qelbree |
| E.R. Squibb & Sons, L.L.C. | $78.82 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $78.59 | 2024-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $68.84 | 2023-2024 | Spravato, Invega |
| Glaxosmithkline, LLC. | $68.83 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $65.20 | 2023-2024 | |
| Sage Therapeutics, LLC | $56.15 | 2024 | |
| Neurocrine Biosciences, INC. | $55.18 | 2023-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $50.71 | 2023-2025 | Austedo Xr, Austedo Xr |
| Idorsia Pharmaceuticals US INC | $50.70 | 2023-2024 | Quviviq |
| Abbott Laboratories | $47.33 | 2024-2025 | Freestyle Libre 3 |
| Corium, LLC | $38.81 | 2025 | Azstarys |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.37 | 2022-2023 | Jardiance |
| Biogen, INC. | $23.99 | 2023 | |
| Neos Therapeutics, Lp | $21.34 | 2024 | Adzenys Xr-Odt |
| Amarin Pharma, INC. | $17.36 | 2021 | |
| Astellas Pharma US INC | $15.61 | 2025 | Veozah |
| Endo Pharmaceuticals INC. | $13.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Doyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.